<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the effects of the usual starting and next higher doses of <z:chebi fb="0" ids="49040">ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> on the cholesterol content of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclasses in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This post hoc analysis compared the effects of treatment with <z:chebi fb="0" ids="49040">ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> 10/20 mg vs. <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 and 20 mg/day and <z:chebi fb="0" ids="49040">ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> 10/40 mg/day vs. <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 40 mg/day on the cholesterol content of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclasses in the modified intent-to-treat (mITT) population (n = 1013) and in subgroups of patients with <z:chebi fb="0" ids="17855">triglyceride</z:chebi> (TG) levels &lt;200 mg/dl (n = 600) and &gt;or=200 mg/dl (2.6 mmol/l) (n = 413) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:chebi fb="0" ids="49040">Ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> significantly reduced <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) subclasses <z:chebi fb="15" ids="39026">LDL</z:chebi>(1)-C, <z:chebi fb="15" ids="39026">LDL</z:chebi>(2)-C and <z:chebi fb="15" ids="39026">LDL</z:chebi>(3)-C; real <z:chebi fb="0" ids="47774">LDL-C</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>(r)); intermediate-density <z:chebi fb="0" ids="50404">lipoprotein cholesterol</z:chebi> (IDL-C), IDL(1)-C, IDL(2)-C; <z:chebi fb="0" ids="47773">very low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47773">VLDL-C</z:chebi>), <z:chebi fb="1" ids="39027">VLDL</z:chebi>(3)-C; and remnant-like <z:chebi fb="0" ids="50404">lipoprotein cholesterol</z:chebi> (RLP-C) from baseline more than <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> at <z:hpo ids='HP_0000001'>all</z:hpo> dose comparisons (p &lt; 0.01) in the mITT population </plain></SENT>
<SENT sid="3" pm="."><plain>Significant improvements were also observed in <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) subclass <z:chebi fb="17" ids="39025">HDL</z:chebi>(3)-C at the <z:chebi fb="0" ids="49040">ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> 10/20 mg vs. <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 20 mg and highest dose comparisons (p &lt; 0.001) and in <z:chebi fb="1" ids="39027">VLDL</z:chebi>(1 + 2)-C at the lowest and highest dose comparisons (p &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Changes in <z:chebi fb="15" ids="39026">LDL</z:chebi>(4)-C and <z:chebi fb="0" ids="47774">LDL-C</z:chebi> subclass patterns (A, B and I) were comparable for both treatments </plain></SENT>
<SENT sid="5" pm="."><plain>Generally, similar results were observed for patients with TG levels &lt;200 and &gt;or=200 mg/dl (2.3 mmol) </plain></SENT>
<SENT sid="6" pm="."><plain>For both treatments, notable differences between TG subgroups were that patients with elevated TGs had smaller reductions in <z:chebi fb="15" ids="39026">LDL</z:chebi>(2)-C, slightly smaller decreases in <z:hpo ids='HP_0000001'>all</z:hpo> IDL subclasses and greater decreases in <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="0" ids="47773">VLDL-C</z:chebi> subclasses than those with lower TG levels </plain></SENT>
<SENT sid="7" pm="."><plain>Frequency of pattern B was also reduced more in patients with higher TGs for both treatments </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="49040">Ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> reduced the cholesterol content of most <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclasses from baseline with generally similar efficacy in patients with low and high TGs </plain></SENT>
<SENT sid="9" pm="."><plain>Despite the different mechanism of action of <z:chebi fb="0" ids="49040">ezetimibe</z:chebi>, the response to <z:chebi fb="0" ids="49040">ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> treatment related to these <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclasses was generally consistent with the overall effects of these therapies on the major <z:chebi fb="23" ids="18059">lipid</z:chebi>/<z:chebi fb="1" ids="6495">lipoprotein</z:chebi> classes </plain></SENT>
<SENT sid="10" pm="."><plain>The clinical significance of these results awaits further study </plain></SENT>
</text></document>